Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Shares Outstanding (Weighted Average) (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Shares Outstanding (Weighted Average) for 12 consecutive years, with $8.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 3.94% year-over-year to $8.6 million, compared with a TTM value of $8.6 million through Sep 2025, up 3.94%, and an annual FY2024 reading of $8.3 million, up 3.17% over the prior year.
  • Shares Outstanding (Weighted Average) was $8.6 million for Q3 2025 at Lisata Therapeutics, up from $8.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $8.6 million in Q3 2025 and bottomed at $8.0 million in Q1 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $8.3 million, with a median of $8.3 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) grew 2.21% in 2024, then increased 3.94% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $8.1 million in 2023, then rose by 3.17% to $8.3 million in 2024, then rose by 3.84% to $8.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for LSTA at $8.6 million in Q3 2025, $8.6 million in Q2 2025, and $8.6 million in Q1 2025.